利德曼跌2.08%，成交额5585.48万元，主力资金净流出585.20万元

Core Viewpoint - Lidman has experienced a decline in stock price and revenue, indicating potential challenges in its business performance and market position [1][2]. Group 1: Stock Performance - As of January 7, Lidman's stock price decreased by 2.08%, trading at 7.05 yuan per share with a total market capitalization of 3.835 billion yuan [1]. - Year-to-date, Lidman's stock has increased by 1.15%, but it has seen a decline of 4.21% over the past 20 days and 6.37% over the past 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Lidman reported a revenue of 252 million yuan, a year-on-year decrease of 10.49%, and a net profit attributable to shareholders of -7.1348 million yuan, a significant decline of 765.83% [2]. - The company has distributed a total of 143 million yuan in dividends since its A-share listing, with 5.4401 million yuan distributed over the past three years [3]. Group 3: Shareholder and Market Position - As of December 31, the number of shareholders in Lidman was 31,100, a decrease of 3.62% from the previous period, with an average of 17,487 circulating shares per shareholder, an increase of 3.76% [2]. - The company operates primarily in the field of in vitro diagnostic reagents, accounting for 67.84% of its revenue, followed by diagnostic instruments at 14.17% and other services at 13.21% [2].